Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614541 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL3139935 | 1.00 | — | — | |
| SCHEMBL276302 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL3623090 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL3614681 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL3625245 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL3619910 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL7062722 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL3622070 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL3614475 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718758-B2 | Aqueous dispersion of colored particles | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| EP-3725854-B1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL CO (JP) | 2023-07-05 | — | — | EP | disclosed |
| CN-111465662-B | Aqueous dispersion of coloured particles | 三菱铅笔株式会社 | 2023-05-26 | — | — | CN | disclosed |
| WO-2021241484-A1 | WRITING IMPLEMENT | 三菱鉛筆株式会社 | 2021-12-02 | — | — | WO | disclosed |
| US-20210071006-A1 | AQUEOUS DISPERSION OF COLORED PARTICLES | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-10913855-B2 | Silicon-containing heterocyclic compound, and quencher | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2021-02-09 | — | — | US | disclosed |
| CN-109071960-B | Silicon-containing heterocyclic matting agents, compounds and polymers | 富士胶片和光纯药株式会社 | 2021-01-12 | — | — | CN | disclosed |
| CN-108473784-B | Polyfunctional polymerizable compound and coloring composition | 富士胶片和光纯药株式会社 | 2021-01-12 | — | — | CN | disclosed |
| EP-3725854-A1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2020-10-21 | — | — | EP | disclosed |
| EP-3165541-B1 | GRAFT POLYMER, RESIN COLORED MATTER, METHOD FOR PRODUCING SAME, AND RESIN COMPOSITION CONTAINING RESIN COLORED MATTER | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-20090023939-A1 | ALPHA-SUBSTITUTED VINYLTIN COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| US-5614550-A | ANTICHOLESTEROL AGENTS OR ARTERIOSCLEROSIS AGENTS FOR HUMANS | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5534529-A | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0632036-A2 | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1995-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913855-B2 | Silicon-containing heterocyclic compound, and quencher | ANXA11, ANXA1, ORAI2 | OPRM1 1980/4885TSHR 3690/4885THRB 3773/4885 |
| US-20090023939-A1 | ALPHA-SUBSTITUTED VINYLTIN COMPOUND | TST, CCNT1, TMT1A | OPRM1 3220/4885TSHR 1353/4885THRB 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.